Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1 +) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST)

Peters, SolangeGadgeel, Shirish M.Mok, Tony S. K.Nadal, ErnestKilickap, SaadettinPerol, MauriceCadranel, Jacques2024-05-192024-05-1920220732-183X1527-7755https://hdl.handle.net/20.500.12713/5978Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2022 -- ELECTR NETWORK[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1 +) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST)Conference Object4017WOS:000891791500036Q1